Retatrutide East Asian Research: Endpoint Evidence Differences
At a glance
- Review question / What do retatrutide records show about study participation and Endpoint Evidence Differences for East Asian populations?
- Best evidence / population-specific registry records and enrollment reporting
- Evidence snapshot / 2026-08-09
- Commercial status / no FDA-approved product or ordinary retail supply
- HealthRX.com role / independent educational review; no retatrutide product or treatment offer
Evidence map for East Asian populations: Endpoint Evidence Differences
| Primary source | What the record documents | What the record cannot establish alone |
|---|---|---|
| ClinicalTrials.gov Chinese-participant record NCT05548231 | A completed phase 1 record in 32 Chinese adults with obesity or overweight. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| ClinicalTrials.gov Japanese-participant record NCT04823208 | A completed phase 1 record in 64 Japanese adults with type 2 diabetes. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| Jastreboff et al., phase 2 obesity trial report | Reports a randomized 48-week study in 338 adults and identifies the protocol-defined endpoints and adverse-event collection methods. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| Rosenstock et al., phase 2 type 2 diabetes trial report | Reports a randomized phase 2 study in 281 adults and describes glycemic, body-weight, and adverse-event endpoints. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
What remains unresolved
Race and ethnicity are not interchangeable with genetics, geography, diet, access to care, or social determinants. Subgroup claims require prespecification, adequate sample size, transparent multiplicity handling, and replication.
What evidence could change the answer
A stronger record would report enrollment, retention, endpoint definitions, missing data, and prespecified subgroup methods for East Asian participants.
Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.
Source records
Snapshot date: 2026-08-09. Records: ClinicalTrials.gov Chinese-participant record NCT05548231; ClinicalTrials.gov Japanese-participant record NCT04823208; Jastreboff et al., phase 2 obesity trial report; Rosenstock et al., phase 2 type 2 diabetes trial report; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs.
Frequently asked questions
What is established about East Asian populations: Endpoint Evidence Differences?
Public sources document study designs, enrolled populations, prespecified endpoints, and regulatory status. They do not establish an FDA-approved indication, public-use instruction, or conclusion beyond those records.
Does this research mean retatrutide is approved or publicly offered?
No. Retatrutide remains investigational, is not available through ordinary commercial prescription or retail sale, cannot be used in compounding under federal law, and is not offered by HealthRX.com.
How can readers verify this review?
Use the linked FDA, eCFR, PubMed, and ClinicalTrials.gov records. Check the source date, study status, population, endpoint definitions, sponsor, and whether results have been peer reviewed.
References
- ClinicalTrials.gov. Retatrutide study record in Chinese adults. 2026. https://clinicaltrials.gov/study/NCT05548231
- ClinicalTrials.gov. Retatrutide study record in Japanese adults. 2026. https://clinicaltrials.gov/study/NCT04823208
- Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
- U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7
